Understanding how microtubules and motors affect cell division accuracy
Microtubule dynamics and error correction
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11031930
This study is looking at how certain proteins help make sure that chromosomes are divided correctly during cell division, which is really important for preventing cancer, and it could lead to new treatments for people with cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11031930 on ClinicalTrials.gov |
What this research studies
This research investigates the role of kinesin-related motors and dynamic microtubules in ensuring accurate chromosome segregation during cell division. By utilizing advanced techniques such as CRISPR/Cas9 and live imaging, the study aims to uncover how specific proteins like MCAK/Kif2C contribute to preventing chromosomal instability, which is crucial for developing effective anti-cancer therapies. The research also explores the functions of other kinesins associated with centrosomes, which play a role in cell division and positioning. Overall, the goal is to provide insights that could lead to new therapeutic targets for cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers characterized by chromosomal instability or those who may benefit from novel anti-cancer therapies targeting microtubule dynamics.
Not a fit: Patients with non-cancerous conditions or those whose cancers do not involve chromosomal instability may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective anti-cancer drugs that improve the accuracy of cell division and reduce chromosomal instability in tumors.
How similar studies have performed: Previous research has shown promising results in targeting microtubule dynamics for cancer treatment, indicating that this approach has potential for success.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WORDEMAN, LINDA — UNIVERSITY OF WASHINGTON
- Study coordinator: WORDEMAN, LINDA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug